Drug-eluting stents in the management of peripheral arterial disease.
Since major meta-analyses of randomized controlled trials in interventional cardiology showed the potential of drug-eluting stents in decreasing restenosis and reintervention rates after coronary artery stenting, one of the next steps in the treatment of arterial occlusive disease is the transfer of the active coating technology towards peripheral arterial interventions. In this manuscript, we aim to provide a literature overview on available peripheral (lower limb, renal, and supra-aortic) drug-eluting stent applications, debate the cost implications, and give recommendations for future treatment strategies.
Bosiers
Marc
M
Department of Vascular Surgery, AZ St-Blasius Dendermonde, Belgium. marc.bosiers@telenet.be
Cagiannos
Catherine
C
Deloose
Koen
K
Verbist
Jürgen
J
Peeters
Patrick
P
D001157:Arterial Occlusive Diseases / Q000473:pathology / Q000628:therapy; D016893:Carotid Stenosis / Q000628:therapy; D003251:Constriction, Pathologic; D054855:Drug-Eluting Stents; D005263:Femoral Artery / Q000473:pathology; D006801:Humans; D016491:Peripheral Vascular Diseases / Q000473:pathology / Q000628:therapy*; D011150:Popliteal Artery / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D012077:Renal Artery / Q000473:pathology; D055502:Secondary Prevention